Long-term clinical benefit with nivolumab and ipilimubab extends beyond treatment discontinuation in patients with metastatic NCSLC, regardless of PD-L1 expression

According to a 5-year follow-up of the CheckMate 227 trial, nivolumab and ipilimumab "continued to demonstrate long-term, durable clinical benefit for previously untreated patients with metastatic non-small cell lung cancer (NSCLC) versus chemotherapy, regardless of tumour PD-L1 expression."   Following a 5-year survival rate of 24% for nivolumab and ipilimumab in PD-L1, the authors of CheckMate 227 concluded that this is the "first phase III study to report 5-year clinical outcomes with a first-line combination of ICIs for patients with metastatic NSLSC." 

To read more about CheckMate 227, click here. 

Source mentioned: Brahmer JR, Lee J-S, Ciuleanu T-E, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227. JCO; Published online 12 October 2022. DOI: 10.1200/JCO.22.01503